Synthesis of One Novel Thieno[2,3-D]Pyrimidine Derivative Bearing a Sulfonylurea Moiety

Abstract:

Article Preview

A novel thieno [2,3-d] pyrimidine compound (1) bearing a sulfonylurea moiety was synthesized from methyl 2-aminothiophene-3-carboxylate (2) through five steps including cyclization, chlorination, substitution with morpholine and piperazine, amidation and its structure was confirmed by 1H NMR and MS spectrum. The total yield of the five steps was 16.2% ( calculated from methyl 2-aminothiophene-3-carboxylate).

Info:

Periodical:

Edited by:

Z.S. Liu, L.P. Xu, X.D. Liang, Z.H. Wang and H.M. Zhang

Pages:

577-580

Citation:

C. Chen et al., "Synthesis of One Novel Thieno[2,3-D]Pyrimidine Derivative Bearing a Sulfonylurea Moiety", Advanced Materials Research, Vol. 1015, pp. 577-580, 2014

Online since:

August 2014

Export:

Price:

$38.00

* - Corresponding Author

[1] Ahmedin Jemal, Freddie Bray, Melissa M., Jacques Ferlay. Global cancer statistics [J]. A Cancer Journal for Clinicians. 2011, 61(2): 69–90.

DOI: https://doi.org/10.3322/caac.20107

[2] Cancer Research UK. New&resources. Worldwide cancer statistics[EB/OL] (2011-9-19) [2012-6-6].

[3] Aranapakam M, Venkatesan M, Christoph M, et al. Bis(morpholino-1, 3, 5-triazine) Derivatives: Potent Adenosine 5'-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound 26(PKI-587), a Highly Efficacious Dual Inhibitor [J]. Journal of Medicinal Chemistry, 53(6), 2636-2645; (2010).

[4] Folkes AJ, Ahmadi K, Alderton W. K, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3, 2-d] pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J. Med. Chem., 2008, 51(18): 5522-5532.

DOI: https://doi.org/10.1021/jm800295d

[4] R.J. Ong, J.T. Dawley and P.G. Clem: submitted to Journal of Materials Research (2003).

[5] Wu Fu Zhu, Xin Zhai, Sai Li, et al. Synthesis and cytotoxic activity of novel 2, 6-disubstituted-4-morpholinothieno[3, 2-d]pyrimidines as potent anti-tumor agents. Chin. Chem. Lett., 2012, 23(6): 703-706.

[6] Wufu Zhu, Xin Zhai, Qiangqiang Fu, et al. Design, synthesis and anticancer activity of 4-morpholinothieno[3, 2-d]pyrimidine derivatives bearing arylmethylene hydrazine moiety. Chem. Pharm. Bull., 2012, 60(8): 1037-1045.

[7] Zhu W, Liu Y, Zhai X, et al. Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno [3, 2-d] pyrimidine derivatives as potential antitumor agents, Euro. J. Med. Chem. 57(2012) 162-175.

DOI: https://doi.org/10.1016/j.ejmech.2012.09.002